These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 38031661)
1. Antiviral peptides inhibiting the main protease of SARS-CoV-2 investigated by computational screening and in vitro protease assay. Stewart J; Shawon J; Ali MA; Williams B; Shahinuzzaman ADA; Rupa SA; Al-Adhami T; Jia R; Bourque C; Faddis R; Stone K; Sufian MA; Islam R; McShan AC; Rahman KM; Halim MA J Pept Sci; 2024 Apr; 30(4):e3553. PubMed ID: 38031661 [TBL] [Abstract][Full Text] [Related]
2. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19. Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441 [TBL] [Abstract][Full Text] [Related]
3. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698 [TBL] [Abstract][Full Text] [Related]
4. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro. Zhou WW; Li DS; Chen Y; You BQ; Zheng YF; Li Y; Si SY; Zhang J Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4313-4325. PubMed ID: 39359203 [TBL] [Abstract][Full Text] [Related]
5. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2021 Aug; 39(12):4362-4374. PubMed ID: 32568613 [TBL] [Abstract][Full Text] [Related]
7. Large scale peptide screening against main protease of SARS CoV-2. Uddin MJ; Akhter H; Chowdhury U; Mawah J; Karim ST; Jomel M; Islam MS; Islam MR; Onin LAB; Ali MA; Efaz FM; Halim MA J Comput Chem; 2023 Mar; 44(8):887-901. PubMed ID: 36478400 [TBL] [Abstract][Full Text] [Related]
8. Biflavonoids from Lokhande K; Nawani N; K Venkateswara S; Pawar S J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454 [TBL] [Abstract][Full Text] [Related]
9. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease. Amaral JL; Oliveira JTA; Lopes FES; Freitas CDT; Freire VN; Abreu LV; Souza PFN J Biomol Struct Dyn; 2022; 40(19):8925-8937. PubMed ID: 33949286 [TBL] [Abstract][Full Text] [Related]
10. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study. Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S Gene; 2024 Oct; 926():148620. PubMed ID: 38821329 [TBL] [Abstract][Full Text] [Related]
11. Investigation of Iminosugars as Antiviral Agents against SARS-CoV-2 Main Protease: Inhibitor Design and Optimization, Molecular Docking, and Molecular Dynamics Studies to Explore Potential Inhibitory Effect of 1-Deoxynojirmycin Series. Miglani V; Sharma P; Kumar Narula A Curr Comput Aided Drug Des; 2023 Aug; ():. PubMed ID: 37612857 [TBL] [Abstract][Full Text] [Related]
12. Depicting the inhibitory potential of polyphenols from Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085 [TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2. Anton DB; Galvez Bulhões Pedreira J; Zvirtes ML; Laufer SA; Ducati RG; Goettert M; Saraiva Macedo Timmers LF J Chem Inf Model; 2023 Jul; 63(13):4138-4146. PubMed ID: 37329322 [TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317 [TBL] [Abstract][Full Text] [Related]
16. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus. Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. Abdizadeh R; Hadizadeh F; Abdizadeh T J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354 [TBL] [Abstract][Full Text] [Related]
18. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2. Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316 [TBL] [Abstract][Full Text] [Related]